

CD262 (DR5) Monoclonal Antibody (DJR2-4 (7-8)), PE, eBioscience™

Product Details	
Size	100 Tests
Species Reactivity	Human
Published Species	Human, Mouse
Host/Isotype	Mouse / IgG1, kappa
Recommended Isotype Control	Mouse IgG1 kappa Isotype Control (P3.6.2.8.1), PE, eBioscience™
Class	Monoclonal
Type	Antibody
Clone	DJR2-4 (7-8)
Conjugate	PE
Form	Liquid
Concentration	5 µL/Test
Purification	Affinity chromatography
Storage buffer	PBS, pH 7.2, with 0.1% gelatin, 0.2% BSA
Contains	0.09% sodium azide
Storage conditions	4° C, store in dark, DO NOT FREEZE!
RRID	AB_10668836

Applications	Tested Dilution	Publications
Immunocytochemistry (ICC/IF)	-	1 Publication
Flow Cytometry (Flow)	5 µL (0.25 µg)/test	34 Publications

Product Specific Information

Description: The DJR2-4 monoclonal antibody reacts with human DR5, also known as TRAIL-R2, Apo2, TRICK2 and KILLER. DR5 binds to TRAIL, activates NF-kappaB, and induces TRAIL-mediated apoptosis. DR5 is expressed broadly by normal tissues as well as several tumor cells.


Applications Reported: The DJR2-4 (a.k.a. 7-8) antibody has been reported for use in flow cytometric analysis.

Applications Tested: This DJR2-4 (a.k.a. 7-8) antibody has been pre-titrated and tested by flow cytometric analysis of normal human peripheral blood cells. This can be used at 5 µL (0.25 µg) per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10⁵ to 10⁸ cells /test.

Excitation: 488-561 nm; **Emission:** 578 nm; **Laser:** Blue Laser, Green Laser, Yellow-Green Laser.

Filtration: 0.2 µm post-manufacturing filtered.


Advanced Verification Data



CD262 (DR5) Antibody (12-9908-42)

Figure 1 Inhibition of proliferation of CCRCC cells by VA and induction of apoptosis. (A) Clonogenic survival assay of VA-treated 786-O cells. 786-O cells were treated with increasing concentrations of VA for 24 hours. After harvesting, cells were seeded at 100 cells/dish in 60-mm dishes in complete medium and allowed to grow for 14 days. Colonies were fixed and stained with crystal violet. (B) Flow cytometric analysis of PI and Annexin V double-stained 786-O and 786-OVHL cells. Cells were treated for 24 hours with 10 nM VA or DMSO. Percentages of cells in each quadrant shown are from one representative experiment. (C) 786-O cells were analyzed by flow cytometry for cell surface expression of DR5. Cells were stained with phycoerythrin (PE)-conjugated isotype control (black) or DR5-PE after control (gray) or VA (unshaded, 10 nM) treatment. (D) CCRCC cells were treated with control, VA (10 nM), TRAIL (20 ng/ml), or VA + TRAIL for 24 hours. Cell viability was assessed using 2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]-2 H -tetrazolium-5-carboxanilide reduction. (E) Time course of Western blot analysis of apoptosis signaling proteins in 786-O cells treated with 10 nM VA. A representative beta-actin blot is shown as a loading control. Cell treatment validation info.

Product Images For CD262 (DR5) Monoclonal Antibody (DJR2-4 (7-8)), PE, eBioscience™



CD262 (DR5) Antibody (12-9908-42) in Flow

Surface staining of human CD262-transfected cells with Mouse IgG1 K Isotype Control PE (Product # 12-4714-81) (open histogram) or Anti-Human CD262 (DR5) PE (filled histogram). Total viable cells were used for analysis.

View more figures on thermofisher.com

35 References

Immunocytochemistry (1)

The Journal of biological chemistry

The farnesyltransferase inhibitor lonafarnib induces CCAAT/enhancer-binding protein homologous protein-dependent expression of death receptor 5, leading to induction of apoptosis in human cancer cells.

"12-9908 was used in Immunofluorescence-cell culture cells to investigate the underlying mechanism by which farnesyltransferase inhibitors cause growth arrest or apoptosis in cancer cells, showing that it induces expression of death receptor 5."

Authors: Sun SY,Liu X,Zou W,Yue P,Marcus AI,Khuri FR

Species
Human

Dilution
1:15

Year
2007

Flow Cytometry (34)

Scientific reports

Death agonist antibody against TRAILR2/DR5/TNFRSF10B enhances birinapant anti-tumor activity in HPV-positive head and neck squamous cell carcinomas.

"Published figure using CD262 (DR5) monoclonal antibody (Product # 12-9908-42) in Flow Cytometry"

Authors: An Y, Jeon J, Sun L, Derakhshan A, Chen J, Carlson S, Cheng H, Silvin C, Yang X, Van Waes C, Chen Z

Species

Human
Not Applicable

Dilution

Not Cited
Not Cited

Year

2021

Cell death & disease

RALB GTPase: a critical regulator of DR5 expression and TRAIL sensitivity in KRAS mutant colorectal cancer.

"Published figure using CD262 (DR5) monoclonal antibody (Product # 12-9908-42) in Flow Cytometry"

Authors: Khawaja H, Campbell A, Roberts JZ, Javadi A, O'Reilly P, McArt D, Allen WL, Majkut J, Rehm M, Bardelli A, Di Nicolantonio F, Scott CJ, Kennedy R, Vitale N, Harrison T, Sansom OJ, Longley DB, Evergren E, Van Schaeuybroeck S

Species

Human
Not Applicable

Dilution

Not Cited
Not Cited

Year

2020

[View more Flow references on thermofisher.com](#)

More applications with references on thermofisher.com

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization. Products are warranted to operate or perform substantially in conformance with published Product specifications in effect at the time of sale, as set forth in the Production documentation, specifications and/or accompanying package inserts ("Documentation"). No claim of suitability for use in applications regulated by FDA is made. The warranty provided herein is valid only when used by properly trained individuals. Unless otherwise stated in the Documentation, this warranty is limited to one year from date of shipment when the Product is subjected to normal, proper and intended usage. This warranty does not extend to anyone other than the Buyer. Any model or sample furnished to Buyer is merely illustrative of the general type and quality of goods and does not represent that any Product will conform to such model or sample. NO OTHER WARRANTIES, EXPRESS OR IMPLIED, ARE GRANTED INCLUDING WITHOUT LIMITATION, IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT. BUYER'S EXCLUSIVE REMEDY FOR NON-CONFORMING PRODUCTS DURING THE WARRANTY PERIOD IS LIMITED TO REPAIR, REPLACEMENT OF OR REFUND FOR THE NON-CONFORMING PRODUCT(S) AT SELLER'S SOLE OPTION. THERE IS NO OBLIGATION TO REPAIR, REPLACE OR REFUND FOR PRODUCTS AS THE RESULT OF (I) ACCIDENT, DISASTER OR EVENT OF FORCE MAJEURE, (II) MISUSE, FAULT OR NEGLIGENCE OF OR BY BUYER, (III) USE OF THE PRODUCTS IN A MANNER FOR WHICH THEY WERE NOT DESIGNED, OR (IV) IMPROPER STORAGE AND HANDLING OF THE PRODUCTS. Unless otherwise expressly stated on the Product or in the documentation accompanying the Product, the Product is intended for research only and is not to be used for any other purpose, including without limitation, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses, or any type of consumption by or application to human or animals.